Development and validation of novel keloid-derived immortalized fibroblast cell lines.
Keloid Disease
hTERT
immortalized cell line
in vitro model
keloid fibroblast
keloid scarring
stable transfection
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
23
10
2023
accepted:
09
04
2024
medline:
25
6
2024
pubmed:
25
6
2024
entrez:
25
6
2024
Statut:
epublish
Résumé
Keloids are a common connective tissue disorder with an ill-understood etiopathogenesis and no effective treatment. This is exacerbated because of the absence of an animal model. Patient-derived primary keloid cells are insufficient as they age through passaging and have a limited supply. Therefore, there is an unmet need for development of a cellular model that can consistently and faithfully represent keloid's pathognomic features. In view of this, we developed keloid-derived immortalized fibroblast (KDIF) cell lines from primary keloid fibroblasts (PKF) by transfecting the human telomerase reverse transcriptase (h
Identifiants
pubmed: 38915394
doi: 10.3389/fimmu.2024.1326728
pmc: PMC11194733
doi:
Substances chimiques
Telomerase
EC 2.7.7.49
TERT protein, human
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1326728Informations de copyright
Copyright © 2024 Sadiq, Khumalo and Bayat.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.